CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net Income (Loss)	$ 8,355	$ 52,046
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	51,306	51,295
Amortization of debt discount and issuance costs	11,628	1,373
Stock-based compensation	41,711	19,110
Deferred income taxes, net	(4,163)	(9,268)
Contingent consideration	0	(31,266)
Non-cash interest income	0	(2,023)
Operating lease right of use asset amortization	12,749	10,203
Other	107	1,275
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable	(4,631)	8,315
Inventories	20,131	25,979
Prepaid expenses and other current assets	(2,609)	(12,749)
Other noncurrent assets	484	(707)
Accounts payable	1,780	(8,619)
Accrued liabilities	5,360	(12,514)
Operating lease liabilities	(5,849)	(7,676)
Noncurrent liabilities	(141)	79
Total cash provided by operating activities	136,218	84,853
Cash flows from investing activities:
Acquisitions, net of cash acquired	0	(27,843)
Proceeds from maturity of marketable securities held to maturity	0	102,323
Additions to capitalized software costs	(2,774)	(2,736)
Purchases of property, plant and equipment	(20,137)	(25,135)
Sale of property, plant and equipment	1,290	21
Total cash (used in) provided by investing activities	(21,621)	46,630
Cash flows from financing activities:
Proceeds from exercise of stock options	2,366	356
Payment of tax withholding obligation on vesting of restricted stock	(9,403)	(12,178)
Repayment of Convertible Senior Notes	(69,939)	(33)
Payment of earnout consideration	(7,375)	(7,298)
Other financing activities	0	(13)
Total cash used in financing activities	(84,351)	(19,166)
Effect of exchange rate changes on cash and cash equivalents	2,395	(4,996)
Net increase (decrease) in cash and cash equivalents	32,641	107,321
Cash, cash equivalents and restricted cash, beginning of period	751,323	523,458
Cash and cash equivalents, end of period	783,964	630,779
Supplemental disclosure of non-cash investing and financing activities:
Assets acquired under operating leases	24,087	1,129
Fair value of shares of common stock issued for contingent consideration earnouts	5,742	7,229
FlexBiosys, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of common stock issued for acquisition	$ 0	$ 5,465